TY - JOUR
T1 - Current drug use patterns and HIV and HCV prevalence among people who inject drugs in suburban areas of Malaysia
AU - Pang, Joselyn
AU - Danaee, Mahmoud
AU - Balasingam Kasinather, Vicknasingam
AU - Des Jarlais, Don
AU - Kamarulzaman, Adeeba
AU - Mohd Salleh, N. A.
N1 - Publisher Copyright:
© 2025 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.
PY - 2025/5
Y1 - 2025/5
N2 - Introduction: National surveillance data in Malaysia has observed a marked reduction in the number of new HIV cases among people who inject drugs (PWID) in the past decade. This study sought to estimate the current prevalence and associated risk factors of HIV and hepatitis C virus (HCV) among PWID in suburban areas of Klang Valley, Malaysia. Methods: Between September 2021 and March 2022, a cross-sectional, respondent-driven sampling survey was conducted. Participants completed rapid HIV and HCV testing as well as social and behavioural assessments. Factors associated with HIV- and HCV-positive results were estimated using logistic regression. Results: Four-hundred individuals were recruited in the study, of whom 382 (94%) were men. The prevalence of HIV and HCV was 5.5% (95% confidence interval [95% CI]: 3.6–8.3) and 40.5% (95% CI: 35.7–45.5), respectively. Current heroin and amphetamine-type stimulant (ATS) use, regardless of injection or non-injection use, were reported by 340 (85.0%) and 328 (82.0%) individuals, respectively. Past exposure to the criminal justice system (lock-ups, prison and compulsory drug detention centres) was associated with both HIV (Adjusted odds ratio [aOR] = 3.47, 95% CI: 1.33–10.2) and HCV (aOR = 3.32, 95% CI: 2.06–5.39)-positive results. Additionally, HIV-positive results were associated with current ATS use (aOR = 0.31, 95% CI: 0.12–0.86). Meanwhile, HCV-positive results were associated with current heroin use (aOR = 2.44, 95% CI: 1.16–5.48), lifetime enrolment in methadone treatment (aOR = 2.30, 95% CI: 1.23–4.27), current methadone treatment (aOR = 0.46, 95% CI: 0.23–0.92) and current mixing of drugs through injection use (aOR = 1.80, 95% CI: 1.08–3.03). Conclusions: This study observed low HIV prevalence among PWID, primarily associated with ATS use, while HCV prevalence, linked to heroin use, remained high. Higher odds of being HCV positive among PWID who reported to have ever but not currently enrolled in methadone programmes indicate that treatment may not be continuous once initiated, potentially due to exposure to the criminal justice system. These findings underscore the need for a dual approach: enhanced harm reduction programmes for PWID and a legal reform to address potential barriers posed by criminalization.
AB - Introduction: National surveillance data in Malaysia has observed a marked reduction in the number of new HIV cases among people who inject drugs (PWID) in the past decade. This study sought to estimate the current prevalence and associated risk factors of HIV and hepatitis C virus (HCV) among PWID in suburban areas of Klang Valley, Malaysia. Methods: Between September 2021 and March 2022, a cross-sectional, respondent-driven sampling survey was conducted. Participants completed rapid HIV and HCV testing as well as social and behavioural assessments. Factors associated with HIV- and HCV-positive results were estimated using logistic regression. Results: Four-hundred individuals were recruited in the study, of whom 382 (94%) were men. The prevalence of HIV and HCV was 5.5% (95% confidence interval [95% CI]: 3.6–8.3) and 40.5% (95% CI: 35.7–45.5), respectively. Current heroin and amphetamine-type stimulant (ATS) use, regardless of injection or non-injection use, were reported by 340 (85.0%) and 328 (82.0%) individuals, respectively. Past exposure to the criminal justice system (lock-ups, prison and compulsory drug detention centres) was associated with both HIV (Adjusted odds ratio [aOR] = 3.47, 95% CI: 1.33–10.2) and HCV (aOR = 3.32, 95% CI: 2.06–5.39)-positive results. Additionally, HIV-positive results were associated with current ATS use (aOR = 0.31, 95% CI: 0.12–0.86). Meanwhile, HCV-positive results were associated with current heroin use (aOR = 2.44, 95% CI: 1.16–5.48), lifetime enrolment in methadone treatment (aOR = 2.30, 95% CI: 1.23–4.27), current methadone treatment (aOR = 0.46, 95% CI: 0.23–0.92) and current mixing of drugs through injection use (aOR = 1.80, 95% CI: 1.08–3.03). Conclusions: This study observed low HIV prevalence among PWID, primarily associated with ATS use, while HCV prevalence, linked to heroin use, remained high. Higher odds of being HCV positive among PWID who reported to have ever but not currently enrolled in methadone programmes indicate that treatment may not be continuous once initiated, potentially due to exposure to the criminal justice system. These findings underscore the need for a dual approach: enhanced harm reduction programmes for PWID and a legal reform to address potential barriers posed by criminalization.
KW - HIV prevention
KW - amphetamine-type stimulant
KW - harm reduction
KW - hepatitis C
KW - heroin use
KW - people who inject drugs
UR - http://www.scopus.com/inward/record.url?scp=105003945806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105003945806&partnerID=8YFLogxK
U2 - 10.1002/jia2.26420
DO - 10.1002/jia2.26420
M3 - Article
C2 - 40285368
AN - SCOPUS:105003945806
SN - 1758-2652
VL - 28
JO - Journal of the International AIDS Society
JF - Journal of the International AIDS Society
IS - 5
M1 - e26420
ER -